<table>
<thead>
<tr>
<th>Subject index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td>S-113</td>
</tr>
<tr>
<td>Activated carbon</td>
<td>S-406</td>
</tr>
<tr>
<td>Adequacy of dialysis</td>
<td>S-3</td>
</tr>
<tr>
<td>Adsorbents</td>
<td>S-397</td>
</tr>
<tr>
<td>Aerobic glycolysis</td>
<td>S-333</td>
</tr>
<tr>
<td>Aliphatic amines</td>
<td>S-314</td>
</tr>
<tr>
<td>Amino acids</td>
<td>S-345</td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td>S-370</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>S-413</td>
</tr>
<tr>
<td>Bone</td>
<td>S-338</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>S-167</td>
</tr>
<tr>
<td>Cardiovascular response</td>
<td>S-263</td>
</tr>
<tr>
<td>Cartilage</td>
<td>S-333</td>
</tr>
<tr>
<td>Charcoal</td>
<td>S-377</td>
</tr>
<tr>
<td>Chemotaxis</td>
<td>S-147</td>
</tr>
<tr>
<td>Clinical trials</td>
<td>S-243</td>
</tr>
<tr>
<td>Collagen</td>
<td>S-97</td>
</tr>
<tr>
<td>Complement</td>
<td>S-323</td>
</tr>
<tr>
<td>Complications</td>
<td>S-30</td>
</tr>
<tr>
<td>Concentration dependence of uremic lesions</td>
<td>S-35</td>
</tr>
<tr>
<td>Creatinine</td>
<td>S-294</td>
</tr>
<tr>
<td>Dialysis</td>
<td>S-413</td>
</tr>
<tr>
<td>Diastolic</td>
<td>S-261</td>
</tr>
<tr>
<td>Distal hemicollagen maturation in end-stage renal insufficiency</td>
<td>S-97</td>
</tr>
<tr>
<td>Electrolytes</td>
<td>S-323</td>
</tr>
<tr>
<td>Enzymes</td>
<td>S-144</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-246</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-249</td>
</tr>
<tr>
<td>Environmental factors</td>
<td>S-222</td>
</tr>
<tr>
<td>Estrogen</td>
<td>S-201</td>
</tr>
<tr>
<td>Electrolytes</td>
<td>S-323</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-246</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-249</td>
</tr>
<tr>
<td>Environmental factors</td>
<td>S-222</td>
</tr>
<tr>
<td>Estrogen</td>
<td>S-201</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-246</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-249</td>
</tr>
<tr>
<td>Environmental factors</td>
<td>S-222</td>
</tr>
<tr>
<td>Estrogen</td>
<td>S-201</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-246</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-249</td>
</tr>
<tr>
<td>Environmental factors</td>
<td>S-222</td>
</tr>
<tr>
<td>Estrogen</td>
<td>S-201</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-246</td>
</tr>
<tr>
<td>Enteral and parenteral nutrition</td>
<td>S-249</td>
</tr>
<tr>
<td>Environmental factors</td>
<td>S-222</td>
</tr>
</tbody>
</table>
Subject index

Dialysis index
quantitative description of dialysis treatment, S-23
Dialysis kinetics
concentration dependence of uremic lesions, S-35
Dialyzer
heparin-grafted hollow fiber dialyzer, S-431
Diet
in uremic hemodialysis patients, S-64
nutritional evaluation of dialysis patients, S-249
Drug therapy
in chronic dialysis patients, S-16
Electroencephalography
neurologic abnormalities in uremia, S-210
Encephalopathy
in uremia, S-194
Erythropoietin
effect of uremic toxins on, S-129
Glomerulonephritis
and hypocomplementemia after transplantation, S-323
Glucose
muscle content of, and hexokinase in uremia, S-341
Glycolysis
of cartilage in uremia, S-333
Growth
in uremia, S-73
Guanidine
toxicity arising from compounds of, S-299
Guanidinopropionic acid
presence and toxicity of, in uremia, S-302
Hematologic disorders
role of dialysis in, in uremia, S-123
Hematologic responses
evaluation in dialysis patients, S-261
shortened red blood cell survival in uremia, S-139
Hemodiafiltration
blood pressure response with maintenance diafiltration, S-413
clinical response to, S-58
Hemodialysis
adequacy of, and cardiovascular complications, S-154
cardiovascular disease in patients on, S-167
cardiovascular response evaluation, S-263
complications, S-30
control of hypertension during, S-184
hematologic response evaluation, S-261
neurological response evaluation, S-256
nutritional evaluation, S-249
optimal, S-365
pharmacokinetic and pharmacodynamic considerations of, S-7
platelet function as an indicator of the adequacy of, S-144
quantification of, in research protocols, S-246
quantitative index of dialysis, S-23
renal osteodystrophy during, S-249
selection of patients for experimental studies, S-222
statistical methods for assessing, S-231
uremic peripheral neuropathy during, S-201
Hemodynamics
of hypertension in uremia, S-155
Hemoglobin
hemodialysis and oxygen binding to, S-134
Hemoperfusion
activated carbon fibers in devices for, S-406
adsorbents in, S-401
by nonbiological particulate matter, S-397
for uremia, intoxication and hepatic failure, S-387
Heparin
grafted hollow fiber dialyzer, S-431
Hexokinase
and muscle glucose content in uremia, S-341
Hollow fiber dialyzer
successful use in sheep, S-431
Home dialysis
past, present and future of, S-418
Hypersensitivity
chemotaxis of leukocytes in uremia, S-147
Hypertension
control of, in hemodialysis, S-184
hemodynamics of, in uremia, S-155
in chronic renal failure, S-176
Hypocomplementemia
and recurrent glomerulonephritis after transplantation, S-323
Intestinal absorption
of calcium in uremia, S-113
Intestinal loop dialysis, inferences from, S-373
Leukocytes
chemotaxis of, in uremia, S-147
Liquid membranes
and chronic uremia, S-409
Membranes
liquid membrane system, S-409
neuropathic toxins and dialysis membranes, S-52
Membranoproliferative glomerulonephritis
recurrent glomerulonephritis and hypocomplementemia after transplantation, S-323
Metabolism
of minerals in uremia, S-85
Methylguanidine
as a uremic toxin, S-299
“Middle” molecules
as toxins, S-349
neuropathy and “middle” molecule toxins, S-352
peptides in uremia, S-272
selective dialysis of, S-361
Mineral
bone mineral-collagen maturation in end-stage renal insufficiency, S-97
Mineral metabolism
in uremia, S-85
Monoamine oxidase
in uremia, S-328
Muscle
glucose content of, and hexokinase in uremia, S-341
Neurobehavioral dysfunction
in uremia, S-217
Neurological aspects
of uremia, S-188, S-210
Subject index

Therapeutic technologies
in uremia, S-267

Selection
of patients for experimental dialysis studies, S-222
Selective dialysis
for removal of large solutes, S-361
Sodium
and the renal pressor system in chronic renal failure, S-176
Sorbents
for removal of nitrogenous metabolites, S-393
in treatment of chronic renal failure, S-383

Optimal dialysis
determination of, S-365

Nutrition
evaluation of dialysis patients, S-249
in uremic hemodialysis patients, S-64
vitamins in hemodialysis patients, S-79

Parathyroid hormone
after calcium carbonate or 25-hydroxycholecalciferol treatment, S-102
metabolism in chronic renal failure, S-90

Pharmacokinetics
considerations for chronic hemodialysis, S-7
in chronic dialysis patients, S-16

Phosphorus
effects on dialysis patients, S-118
hemodialysis and intraerythrocytic phosphate compounds, S-134

Platelets
as an indicator of adequate dialysis, S-144

Polyaldehydes
oxycellulose and ammonia-treated oxystarch as, S-380

Pressor system
and sodium in chronic renal failure, S-176
Protein
in uremic hemodialysis patients, S-64

Psychological alterations
in uremia, S-217
Psychological studies
of the uremic state, S-206

Red blood cell
shortened survival in uremia, S-139

Rejection
in kidney transplantation, S-318
Research
to define adequacy of dialysis, S-3
Research protocols
quantification of dialysis therapy in, S-246

Selection
of patients for experimental dialysis studies, S-222
Selective dialysis
for removal of large solutes, S-361
Sodium
and the renal pressor system in chronic renal failure, S-176
Sorbents
for removal of nitrogenous metabolites, S-393
in treatment of chronic renal failure, S-383

Starch
as insoluble polyaldehyde in uremia, S-380
life prolongation in nephrectomized rats fed, S-377

Statistical methods
for assessing adequacy of dialysis, S-231

Therapeutic technologies
in uremia, S-267

Toxins
uremic, effect on erythropoietin, S-129
uremic metabolite screening, S-45
uremic, search for, S-270

Transplantation
metabolism in chronic renal failure, S-90
clinical, Artificial Kidney-Chronic Uremic Program, S-243

Trials
uremic metabolite screening, S-45
uremic, search for, S-270

Tryptophan
metabolism of, in uremia, S-311

Urea
toxicity arising from S-288
Urea cycle
in uremia, S-280
toxicity arising from S-285

Uremia
amino acids in, S-306
cardiovascular disease in, S-167
encephalopathy in, S-194
hemodynamics of hypertension in, S-155
molecular etiology of, S-276
peptides of "middle" molecular weight in, S-272
search for uremic toxins, S-270
therapeutic technologies in, S-267
toxicity arising from urea, S-288
tryptophan metabolism in, S-311
urea cycle and toxicity, S-285

Vitamin D
bone histomorphometry and serum mineral and parathyroid hormone values after administration of, S-102
metabolism in chronic renal failure, S-90

Vitamins
nutrition in hemodialysis patients, S-79